Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By boosting these receptors, Retatrutide controls cravings, {promotesenergy expenditure, tb-500 dosage and ultimately contributes to significant wei